26 September 2023
In a wide-ranging interview with Justin Petrone for GenomeWeb’s 360Dx, Diagnostics for the Real World CEO and Chairman Dr Helen Lee and COO Craig Wisniewski talk exclusively about DRW’s new assays – the SAMBA II SARS-CoV-2/Flu and SAMBA II SARS-CoV-2/RSV multiplex tests – plus the company’s plans for the third-generation SAMBA platform, now in development.
Read the full article here (requires subscription to view).
Browse other related news and activities
Leading NHS hospitals have adopted the SAMBA III rapid molecular diagnostics platform to transform the way patients with suspected respiratory infections are assessed and managed. “Using SAMBA III will give us greater flexibility meaning that our patients are cared for in the...
29 September 2025
Diagnostics for the Real World (DRW) is pleased to announce that its SAMBA III SARS-CoV-2 Test and SAMBA III SCoV-2/Flu/RSV Test have received approval under the UK Coronavirus Test Device Approvals (CTDA) process. Following a successful desktop review by the UK’s Medicines and Healthcare...
8 August 2025
Diagnostics for the Real World (DRW), a pioneer in rapid molecular diagnostics, today announces the launch of the SAMBA III Instrument System – its most advanced point-of-care molecular platform to date. Building on more than two decades of innovation, SAMBA III has...
20 April 2025
